Nordion agrees to produce MI agent

June 28, 2004

MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new

MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new radiopharmaceutical, 123I-BMIPP (123I-beta-methyl-iodophenylpentadecanoic acid), for detection of cardiac ischemia in the emergency department. The cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, BC.